Novartis, China firm sign US$1.7 billion deal to develop Alzheimer’s drugs
www.scmp.com
SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

A partnership between China’s SciNeuro Pharmaceuticals and Swiss pharmaceutical giant Novartis on Monday has revived hopes for treating Alzheimer’s disease. The deal, worth nearly US$1.7 billion, grants Novartis exclusive worldwide rights to develop and commercialise SciNeuro’s antibody candidates to develop drugs for the progressive brain disease. SciNeuro’s novel amyloid beta targeted antibody programme leverages proprietary blood-brain barrier shuttle technology to help more of the drug cross…

From China - South China Morning Post via This RSS Feed.